In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 6, 2006, Pages 441-450

  Assié, Marie Bernadette ^a   Dominguez, Hélène ^a   Consul Denjean, Nathalie ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

3H nemonapride; Antipsychotic; Dopamine D2 receptors; In vivo receptor binding; Mouse brain

Indexed keywords

1 (2,3 DIHYDROBENZO[1,4]DIOXIN 5 YL) 4 [5 (4 FLUOROPHENYL)PYRIDIN 3 YLMETHYL]PIPERAZINE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; [(3 EXO) 8 BENZOYL N [(7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL)METHYL] 8 AZABICYCLO(3.2.1)OCTANE 3 METHANAMINE; APOMORPHINE; ARIPIPRAZOLE; BIFEPRUNOX; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EMONAPRIDE; ETICLOPRIDE; HALOPERIDOL; LIGAND; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SARIZOTAN; SEROTONIN 1A RECEPTOR; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGONIST; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CATALEPSY; CLIMBING; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DRUG ACTIVATION; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZAMIDES; BINDING, COMPETITIVE; CATALEPSY; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; NEOSTRIATUM; OLFACTORY BULB; RECEPTORS, DOPAMINE D2; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 33748752501     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0092-z     Document Type: Article

References (57)

1. Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15-27
2. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
3. 3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex. Pharmacology 75:63-68
4. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46
5. 1A agonist properties. Neuropsychopharmacology In Press
6. 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 111:113-126
7. 1A agonists in the treatment of depression? Biol Psychiatry 53:193-203
8. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420
9. Brevik A, Farver D (2003) Atypical antipsychotic induced mild hypothermia. S D J Med 56:67-70
10. Broekkamp CL, Oosterloo SK, Berendsen HH, van Delft AM (1988) Effect of metergoline, fenfluramine, and 8-OH-DPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338:191-195
11. 2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70
12. Burstein ES, Ma JN, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005) Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287
13. 1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28:2064-2076
14. Cosi C, Carilla-Durand E, Assié M-B, Ormière A-M, Maraval M, Leduc N, Newman-Tancredi A (2006) Partial agonist properties of the antipsychotics SSR181507, aropiprazole and bifeprunox ant dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135-144
15. Den Boer JA, Korf J (2000) Dopamine receptor subtypes and schizophrenia: a clinical perspective. In: Ellenbroek BA, Cools AR (eds.) Atypical antipsychotics. Birkhäuser, Basel, pp 163-190
16. 1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28:1889-1902
17. Eltayb A, Wadenberg MLG, Schilström B, Svensson TH (2005) Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol 372:195-202
18. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron Emission Tomographic Analysis of Central D1-Dopamine and D2-Dopamine Receptor Occupancy in Patients Treated with Classical Neuroleptics and Clozapine - Relation to Extrapyramidal Side Effects. Arch Gen Psychiatry 49:538-544
19. Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974-977
20. 4 receptors. Br J Pharmacol 117:1625-1632
21. Ichikawa J, Meltzer HY (1999) Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiat Clin Neuros 249:90-98
22. 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
23. 2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies. J Neural Transm 97:119-133
24. 2 receptors. Prog Neuropsychopharm Biol Psychiatry 27:1081-1090
25. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a pet study. Life Sci 57:PL103-PL107
26. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
27. 1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49:135-143
28. Kobilka B (1992) Adrenergic receptors as models for G proteincoupled receptors. Annu Rev Neurosci 15:87-114
29. 3 receptor. Neurotox Res 6:63-71
30. 1A Receptor Agonist Potential Antipsychotic Drug. Neuropsychopharmacology (In press)
31. McMillen BA, Scott SM, Davanzo EA (1988) Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
32. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors : their key role in drugs to treat schizophrenia. Prog Neuropsychopharm Biol Psychiatry 27:1159-1172
33. 1A receptors. J Pharmacol Exp Ther 295:853-861
34. Moss LE, Neppe VM, Drevets WC (1993) Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13:204-209
35. 2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology (In press)
36. 1A receptors: affinity, efficacy and potential implication for treatment of schizophrenia. Int J Neuropsychopharmacol 11:1-16
37. Oerther S, Ahlenius S (2000) Atypical antipsychotics and dopamine D1 receptor agonism: An in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 292:731-736
38. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82
39. 2 dopamine receptor occupancy in clozapine-treated patients. Am J Psychiatry 153:1571-1578
40. Prinssen EPM, Kleven MS, Koek W (1998) The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties. Eur J Pharmacol 356:189-192
41. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
42. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73
43. 2 receptors. Life Sci 60:PL207-PL216
44. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884
45. 125I] epidepride. Eur J Pharmacol 286:R3-R5
46. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
47. Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz JC (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659-666
48. 1A receptors in the mouse brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 364:479-486
49. 2 receptor occupancy. Neuropsychopharmacology 12:57-64
50. 1A agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868
51. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2006) Aripiprazole has Functionally Selective Actions at Dopamine D (2) Receptor-Mediated Signaling Pathways. Neuropsychopharmacology (In press)
52. Wadenberg MLG (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339
53. Wadenberg MLG, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53
54. Wadenberg MLG, Kapur S, Soliman A, Jones C, Vaccarino F (2000) Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429
55. Wolf W (2003) DU-127090. Curr Opin Investig Drugs 4:72-76
56. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508
57. Yoshida K, Sugita R, Higuchi H, Hishikawa Y (1998) Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry 13:421-422